Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
shark cartilage extract AE-941 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| shark cartilage extract AE-941 | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed renal cell adenocarcinoma Disease progression within 16 weeks after first-line therapy, which included interleukin-2 and/or interferon Metastatic disease not amenable to surgery Measurable and/or evaluable disease No more than one line of prior antic...
Top 20 of 38 competitors
Shark cartilage extract AE-941 is an investigational small molecule oncology agent developed by COSCIENS Biopharma Inc., which trades under the ticker CSCI. It has been studied in kidney cancer and in multiple myeloma and plasma cell neoplasm. It is not an approved therapy and remains in clinical development.
Shark cartilage extract AE-941 has been studied for the treatment of metastatic kidney cancer and for relapsed or refractory multiple myeloma and plasma cell neoplasm. Both are oncology indications. The agent is investigational, so it is not an approved treatment for these or any other condition.
Shark cartilage extract AE-941 is developed by COSCIENS Biopharma Inc., a company whose shares trade under the ticker CSCI. COSCIENS is the sponsor associated with the clinical development of AE-941 in kidney cancer and in multiple myeloma and plasma cell neoplasm.
Shark cartilage extract AE-941 has reached Phase 3 development. The Phase 3 study was conducted in metastatic kidney cancer, while a separate Phase 2 study was conducted in relapsed or refractory multiple myeloma. The agent is investigational and is not approved by the FDA.
Shark cartilage extract AE-941 has been evaluated in two completed trials. NCT00005995 was a Phase 3 study in patients with metastatic kidney cancer, and NCT00022282 was a Phase 2 study in patients with relapsed or refractory multiple myeloma. Both trials were conducted in Canada and enrolled adults.